Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29337480 | 0.83 | PDXK (0.36) | KMT2AHTTDYRK1AMEN1MAPT | |
| SCHEMBL10684726 | 0.78 | KMT2A (0.46) | ERN1KMT2AHTTALDH1A1DYRK1A | |
| SCHEMBL28518576 | 0.77 | ERN1 (0.41) | ERN1KMT2AHTTALDH1A1DYRK1A | |
| SCHEMBL3025399 | 0.76 | CNR2 (0.33) | KMT2AHTTMEN1MAPTPKM | |
| SCHEMBL3025395 | 0.76 | CNR2 (0.33) | KMT2AHTTMEN1MAPTPKM | |
| SCHEMBL13244920 | 0.75 | HTT (0.34) | KMT2AHTTALDH1A1DYRK1AAURKA | |
| SCHEMBL13119995 | 0.75 | PLAU (0.42) | KMT2AHTTALDH1A1DYRK1AAURKA | |
| SCHEMBL21682414 | 0.75 | HTT (0.43) | KMT2AHTTALDH1A1DYRK1AAURKA | |
| SCHEMBL31613762 | 0.75 | KCNJ1 (0.37) | KMT2AHTTALDH1A1DYRK1AAURKA | |
| SCHEMBL2567586 | 0.75 | KMT2A (0.34) | KMT2AHTTALDH1A1DYRK1AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4724440-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Interline Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260028348-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4594307-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-02-20 | — | — | US | disclosed |
| EP-4491622-A2 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024254539-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-116249554-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11472796-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022069520-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-04-07 | — | — | WO | disclosed |
| US-20210147399-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3740481-A1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10836755-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| CN-111757875-A | Dihydrobenzofuran and indene analogs as inotropic agents | 赛特凯恩蒂克公司 | 2020-10-09 | — | — | CN | disclosed |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2019-08-22 | — | — | US | disclosed |
| WO-2019144041-A1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | ERN1 727/4885KMT2A 3501/4885HTT 3581/4885 |
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | NR3C1, CCR1, CXCR2 | ERN1 1481/4885KMT2A 3967/4885HTT 1434/4885 |
| US-10836755-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | ERN1 727/4885KMT2A 3501/4885HTT 3581/4885 |
| US-20210147399-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | ERN1 727/4885KMT2A 3501/4885HTT 3581/4885 |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | TNNT2, TNNI3, TNNC1 | ERN1 1366/4885KMT2A 3822/4885HTT 1170/4885 |
| US-11472796-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | ERN1 727/4885KMT2A 3501/4885HTT 3581/4885 |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | ERN1 727/4885KMT2A 3501/4885HTT 3581/4885 |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | ERN1 2477/4885KMT2A 3454/4885HTT 343/4885 |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | ERN1 2477/4885KMT2A 3454/4885HTT 343/4885 |
| US-20260028348-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, TNFRSF9 | ERN1 1146/4885KMT2A 4607/4885HTT 2924/4885 |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | ERN1 727/4885KMT2A 3501/4885HTT 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.